Condition (MeSH)
Xerophthalmia
ClinicalTrials.gov lists 29 trials for Xerophthalmia or a narrower condition beneath it. Taipei Veterans General Hospital, Taiwan has the most among industry and government lead sponsors, with 5.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
29 of the 29 trials are tagged with Xerophthalmia itself; the rest are tagged with a narrower condition beneath it.
When did Xerophthalmia trials start? (16)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 4 |
| 2024 | 4 |
| 2023 | 2 |
| 2022 | 2 |
| 2021 | 1 |
| 2020 | 2 |
| 2019 | 1 |
| 2018 | 2 |
| 2016 | 3 |
Showing 10 of 16 earlier years.
No forecast is made for this condition: it averages 2.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Xerophthalmia trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 5 |
| Phase 3 | 2 |
| Phase 4 | 2 |
| Not applicable | 12 |
| Observational | 6 |
How many Xerophthalmia trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 4 |
| Recruiting | 4 |
| Enrolling by invitation | 1 |
| Completed | 13 |
| Withdrawn | 2 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Xerophthalmia trials? (9)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Taipei Veterans General Hospital, Taiwan | 5 |
| Dompé Farmaceutici S.p.A | 2 |
| Abbott Medical Optics | 1 |
| Avizor SA | 1 |
| Bio Nature Health | 1 |
Showing 5 of 9 sponsors.
Interventions as named in the registry (15)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Acupuncture | 3 |
| Metabolomics | 1 |
| Sodium Hyaluronate 1% | 1 |
| Chinese herbal tea TBDESJS | 1 |
| NCP112 | 1 |
Showing 5 of 15 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Xerophthalmia trials report? (7)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Amaurosis fugax | 1 | 1 |
| Cardiac failure | 1 | 1 |
| Herpes zoster | 1 | 1 |
| Ischaemic stroke | 1 | 1 |
| Lymphopenia | 1 | 1 |
Showing 5 of 7 adverse events.
Which publications cover Xerophthalmia? (25)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Red palm olein supplementation as a potential preventive solution for xerophthalmia among vitamin A-deficient primary schoolchildren: a cluster randomized controlled trial. | European journal of clinical nutrition | 2025 | Yes |
| Pilocarpine and artificial saliva for the treatment of xerostomia and xerophthalmia in Sjögren syndrome: a double-blind randomized controlled trial. | The British journal of dermatology | 2018 | Yes |
| Dry Eye Disease: Prevalence, Assessment, and Management. | Home healthcare now | 2018 | Yes |
| Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). | Annals of the rheumatic diseases | 2015 | Yes |
| Meibomian gland dysfunction determines the severity of the dry eye conditions in visual display terminal workers. | PloS one | 2014 | Yes |
Showing 5 of 25 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.